237 related articles for article (PubMed ID: 24862760)
1. VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2.
Lim JJ; Yang K; Taylor-Harding B; Wiedemeyer WR; Buckanovich RJ
Neoplasia; 2014 Apr; 16(4):343-53.e1-2. PubMed ID: 24862760
[TBL] [Abstract][Full Text] [Related]
2. VEGFR3 inhibition chemosensitizes lung adenocarcinoma A549 cells in the tumor-associated macrophage microenvironment through upregulation of p53 and PTEN.
Li Y; Weng Y; Zhong L; Chong H; Chen S; Sun Y; Li W; Shi Q
Oncol Rep; 2017 Nov; 38(5):2761-2773. PubMed ID: 29048623
[TBL] [Abstract][Full Text] [Related]
3. RARα mediates all-trans-retinoic acid-induced VEGF-C, VEGF-D, and VEGFR3 expression in lung cancer cells.
Kalitin NN; Karamysheva AF
Cell Biol Int; 2016 Apr; 40(4):456-64. PubMed ID: 26818829
[TBL] [Abstract][Full Text] [Related]
4. ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature.
Roy L; Samyesudhas SJ; Carrasco M; Li J; Joseph S; Dahl R; Cowden Dahl KD
Oncotarget; 2014 Sep; 5(18):8355-66. PubMed ID: 25327563
[TBL] [Abstract][Full Text] [Related]
5. Tumor-derived exosomal BCYRN1 activates WNT5A/VEGF-C/VEGFR3 feedforward loop to drive lymphatic metastasis of bladder cancer.
Zheng H; Chen C; Luo Y; Yu M; He W; An M; Gao B; Kong Y; Ya Y; Lin Y; Li Y; Xie K; Huang J; Lin T
Clin Transl Med; 2021 Jul; 11(7):e497. PubMed ID: 34323412
[TBL] [Abstract][Full Text] [Related]
6. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
[TBL] [Abstract][Full Text] [Related]
7. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
Birkbak NJ; Kochupurakkal B; Izarzugaza JM; Eklund AC; Li Y; Liu J; Szallasi Z; Matulonis UA; Richardson AL; Iglehart JD; Wang ZC
PLoS One; 2013; 8(11):e80023. PubMed ID: 24265793
[TBL] [Abstract][Full Text] [Related]
8. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.
Yang H; Kim C; Kim MJ; Schwendener RA; Alitalo K; Heston W; Kim I; Kim WJ; Koh GY
Mol Cancer; 2011 Apr; 10():36. PubMed ID: 21481239
[TBL] [Abstract][Full Text] [Related]
9. Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells.
Spinella F; Caprara V; Di Castro V; Rosanò L; Cianfrocca R; Natali PG; Bagnato A
J Mol Med (Berl); 2013 Mar; 91(3):395-405. PubMed ID: 22965194
[TBL] [Abstract][Full Text] [Related]
10. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
11. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
George J; Alsop K; Etemadmoghadam D; Hondow H; Mikeska T; Dobrovic A; deFazio A; ; Smyth GK; Levine DA; Mitchell G; Bowtell DD
Clin Cancer Res; 2013 Jul; 19(13):3474-84. PubMed ID: 23633455
[TBL] [Abstract][Full Text] [Related]
12. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
13. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
14. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.
Curley MD; Therrien VA; Cummings CL; Sergent PA; Koulouris CR; Friel AM; Roberts DJ; Seiden MV; Scadden DT; Rueda BR; Foster R
Stem Cells; 2009 Dec; 27(12):2875-83. PubMed ID: 19816957
[TBL] [Abstract][Full Text] [Related]
15. Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.
Sopo M; Anttila M; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Sallinen H
BMC Cancer; 2019 Jun; 19(1):584. PubMed ID: 31200683
[TBL] [Abstract][Full Text] [Related]
16. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
[TBL] [Abstract][Full Text] [Related]
18. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.
Silva IA; Bai S; McLean K; Yang K; Griffith K; Thomas D; Ginestier C; Johnston C; Kueck A; Reynolds RK; Wicha MS; Buckanovich RJ
Cancer Res; 2011 Jun; 71(11):3991-4001. PubMed ID: 21498635
[TBL] [Abstract][Full Text] [Related]
19. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
20. Roles of vascular endothelial growth factor receptor 3 signaling in differentiation of mouse embryonic stem cell-derived vascular progenitor cells into endothelial cells.
Suzuki H; Watabe T; Kato M; Miyazawa K; Miyazono K
Blood; 2005 Mar; 105(6):2372-9. PubMed ID: 15561887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]